The DOI matches its Crossref record, with a small difference in title or year; 27 of the 27 references it cites were found in a registry or an index.
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study
Open accessAbstract
Background and objectives: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate–associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial. Design, setting, participants, & measurements: In the correction phase, adult outpatients with plasma potassium ≥5.1 mmol/L (i-STAT Point-of-Care) received sodium zirconium cyclosilicate 10 g three times daily for 24–72 hours until normokalemic (potassium =3.5–5.0 mmol/L). Qualifying participants entered the ≤12-month maintenance phase and received sodium zirconium cyclosilicate 5 g once daily titrated to maintain normokalemia without dietary or medication restrictions. Prespecified primary end points were restoration of normal serum potassium values (3.5–5.0 mmol/L) during the correction phase and maintenance of serum potassium ≤5.1 mmol/L during the maintenance phase. Adverse events were assessed throughout. Results: Of 751 participants, 746 (99%) achieved normokalemia during the correction phase (mean serum potassium =4.8 mmol/L; 95% confidence interval, 4.7 to 4.8) and entered the maintenance phase; 466 (63%) participants completed the 12-month trial. Participants were predominantly white, men, and age ≥65 years old; 74% had an eGFR<60 ml/min per 1.73 m 2 , and 65% used renin-angiotensin-aldosterone system inhibitors. Mean time on sodium zirconium cyclosilicate was 286 days. Mean daily sodium zirconium cyclosilicate dose was 7.2 g (SD=2.6). Over months 3–12, mean serum potassium was 4.7 mmol/L (95% confidence interval, 4.6 to 4.7); mean serum potassium values ≤5.1 and ≤5.5 mmol/L were achieved by 88% and 99% of participants, respectively. Of 483 renin-angiotensin-aldosterone system inhibitor users at baseline, 87% continued or had their dose increased; 11% discontinued. Among 263 renin-angiotensin-aldosterone system inhibitor–naïve participants, 14% initiated renin-angiotensin-aldosterone system inhibitor therapy. Overall, 489 (66%) participants experienced adverse events during the maintenance phase, and 22% experienced a serious adverse event. Of eight (1%) deaths, none were considered related to sodium zirconium cyclosilicate. Nine (1%) and 34 (5%) participants experienced serum potassium <3.0 and 3.0–3.4 mmol/L, respectively. Conclusions: After achieving normokalemia, individualized once daily sodium zirconium cyclosilicate was associated with maintenance of normokalemia without substantial renin-angiotensin-aldosterone system inhibitor changes for ≤12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, clinical outcomes were not evaluated;”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ef fi cacy and safety data beyond 1 year of treatment are not available;”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with potassium binders, such as patiromer or sodium zirconium cyclosilicate, where each has been used to treat hyperkalemia associated with RAS blockade therapy for up to 12 months. 83,84”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both studies demonstrated the effectiveness of achieving normokalemia and that treatment with RAS blockade agents can be continued without treatment-related serious adverse effects.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J. T., Christ‐Schmidt, H., Berman, L., & Pitt, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 683
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 655
Sodium Zirconium Cyclosilicate in Hyperkalemia
Packham, D., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G. A., Qunibi, W. Y., Pérgola, P. E., & Singh, B. P. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411487 · Cited by 505
Self-citationAvosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S., Littke, T., & Viberti, G. C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 501
Kosiborod, M., Rasmussen, H. S., Lavin, P. T., Qunibi, W. Y., Spinowitz, B., Packham, D., Roger, S. D., Yang, A., Lerma, E. V., & Singh, B. P. (2014) · JAMA · doi:10.1001/jama.2014.15688 · Cited by 414
Self-citationHarel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J. M., & Bell, C. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.016 · Cited by 324
Ion-Exchange Resins for the Treatment of Hyperkalemia
Sterns, R. H., Rojas, M. P. L., Bernstein, P. L., & Chennupati, S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010079 · Cited by 303
Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function
Luo, J., Brunelli, S. M., Jensen, D. E., & Yang, A. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01730215 · Cited by 288
Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease
Jain, N., Kotla, S. K., Little, B. B., Weideman, R. A., Brilakis, E. S., Reilly, R. F., & Banerjee, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.367 · Cited by 219
McGill, J. B., Sloan, L. A., Newman, J., Patel, S. D., Sauce, C., von Eynatten, M., & Woerle, H. (2012) · Diabetes Care · doi:10.2337/dc12-0706 · Cited by 203
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–198 of 198
Fravel, M. A., Meaney, C. J., & Noureddine, L. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01265-1 · Cited by 8
Pollack, C. V., Arroyo, D., Kanda, E., Sánchez-Lázaro, I. J., Lesén, E., Franzén, S., Gray, C. M., Lipińska, A., Murohara, T., & Rastogi, A. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15171 · Cited by 5
Cheung, T. T., Sun, F., Zhao, J., Qin, Y., & Någård, M. B. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1055 · Cited by 5
Self-citationZhou, J., Jin, X., Zhou, J. F., Xu, Y., Cui, X., Fu, M., Hu, K., Ge, J., & the CN‐HF Investigators (2023) · Clinical Cardiology · doi:10.1002/clc.24114 · Cited by 5
Kimura, W., Minatoguchi, S., Mizuno, T., Koide, S., Hayashi, H., Hasegawa, M., Inaguma, D., & Tsuboi, N. (2023) · Journal of Nephrology · doi:10.1007/s40620-023-01743-4 · Cited by 5
Rastogi, A., Hanna, R. M., Mkrttchyan, A., Khalid, M., Yaqoob, S., Shaffer, K. C. L., Dhawan, P., Nobakht, N., Kamgar, M. K., Goshtaseb, R., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1932460 · Cited by 5
Self-citationGray, J. P., & Ray, S. D. (2020) · Side effects of drugs annual · doi:10.1016/bs.seda.2020.09.012 · Cited by 5
Epstein, M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.01.032 · Cited by 5
González-Ortíz, A., Clase, C. M., Bosi, A., Fu, E. L., Pérez-Guillé, B., Faucon, A., Evans, M., Zoccali, C., & Carrero, J. J. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01860-0 · Cited by 4
Sodium Zirconium Cyclosilicate in CKD, Hyperkalemia, and Metabolic Acidosis
Ash, S. R., BATLLE, D. C., Kendrick, J., Oluwatosin, Y. E., Kooienga, L. A., Eudicone, J. M., Sundin, A.-K., Guerrieri, E., & Fried, L. F. (2024) · Kidney360 · doi:10.34067/kid.0000000000000446 · Cited by 4
The burden of hyperkalaemia on hospital healthcare resources
Ellis, H. L., Al-Agil, M., Kelly, P. A., Teo, J., Sharpe, C. C., & Whyte, M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01452-7 · Cited by 4
Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease
Kassem, H. S., & Chatila, K. F. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000583 · Cited by 4
Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…
Carrero, J. J., Sood, M. M., González-Ortíz, A., & Clase, C. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad089 · Cited by 4
Strategies for the Management of Cardiorenal Syndrome in the Acute Hospital Setting
Chandramohan, D., Simhadri, P. K., Jena, N. K., & Palleti, S. K. (2024) · Hearts · doi:10.3390/hearts5030024 · Cited by 4
Xu, H., Liu, J., Gu, L., Zang, X., Liu, N., Pan, Y., Jiang, C., Li, Y., Jiang, G., Mao, Z., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112413 · Cited by 3
Hoorn, E. J., Subramanya, A. R., & Boyd‐Shiwarski, C. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01053-5 · Cited by 3
Geraci, G., Sinatra, N., Paternò, V., Calabrese, V., Cassataro, G., Cuttone, G., Geraci, C., Esposito, R., Mancusi, C., Pucci, G., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07890-7 · Cited by 3
An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China
Lu, Y. Q., Liu, B., & Liu, H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161884 · Cited by 3
Qu, X., Yan, H., & Khan, B. A. (2023) · Cureus · doi:10.7759/cureus.45058 · Cited by 3
Agiro, A., Dwyer, J. P., Oluwatosin, Y. E., & Desai, P. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s420217 · Cited by 3
Chay, J., Choo, J. C. J., & Finkelstein, E. A. (2024) · Nephrology · doi:10.1111/nep.14284 · Cited by 3
Liang, X., Lu, W., Yu, X., Cheng, H., He, Q., Peng, Q., Ni, Z., Long, G., Wang, L., Chen, W., et al. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.07.004 · Cited by 3
Self-citationZhang, L.-H., Cen, Z., Qiao, Q., Ye, X.-R., Cheng, L., Liu, G.-Q., Liu, Y., Zhang, X.-Q., Pan, X.-F., Zhang, H.-L., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.109044 · Cited by 3
Burton, J. O., Allum, A. M., Amin, A. J., Linde, C. M., Lesén, E., Mellström, C., Eudicone, J. M., & Sood, M. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad053 · Cited by 3
Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem
Abrignani, M. G., Gronda, E., Marini, M., Gori, M., Iacoviello, M., Temporelli, P. L., Benvenuto, M., Binaghi, G., Cesaro, A., Maloberti, A., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07551-7 · Cited by 4
Elsisi, G. H., Mahmoud, M. M. I., Al-Humood, K., & Alyousef, A. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2314930 · Cited by 3
Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15617 · Cited by 3
Shen, N., Zhang, L., Yang, J. H., Lin, Y., Liu, X., Cai, X., Cao, J., Zhu, Q., Luo, X., Wan, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398953 · Cited by 3
Self-citationSafety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis
Yu, Y., Zhang, K., Gao, J., Huang, G., Yong, C., Wei, Y., & Zhou, E. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320585 · Cited by 3
Chen, J., Lu, Z., Luo, H., Wang, T., & Qin, X. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2486310 · Cited by 3
Wadhwa, N. K., Kline, J. A., & Adapa, S. (2021) · Case Reports in Nephrology · doi:10.1155/2021/6987456 · Cited by 3
An Alternative to Sodium Polystyrene Sulfonate and Patiromer for the Treatment of Hyperkalemia—Reply
Grady, D. G., & Parks, M. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.4685 · Cited by 3
Ng, J. K., Fung, W. W., Chan, G. C., Chow, K., & Szeto, C. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04194-0 · Cited by 2
Rethinking Potassium Management in Chronic Kidney Disease—A Modern Approach
Kog, Z. X., Lee, I. W. Z., & Teh, S. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248917 · Cited by 2
Furuland, H., Larsson, A. O., Uhde, M., Parv, K., Almstedt, M., Cars, T., & Svensson, M. K. E. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70087 · Cited by 3
Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate
Jung, J. A., Juarez, S., Koh, E. S., & Chung, S. (2026) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2026.24.e3 · Cited by 3
Jiang, Y., Fang, Y., FangHong, G., Wang, H. B., Zhang, C., Zhang, H., Zhou, W., & Zhang, Y. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05286-y · Cited by 2
Alcázar-Arroyo, R., Crespo‐Leiro, M. G., Bover, J., Oliva, J., Mutiozabal, M. S., Gradari, S., Marinez-Lopez, A., López-Chicheri, B., Vidal-Vilar, N., Aceituno, S., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.02.006 · Cited by 2
Management of hyperkalemia: Expert consensus from Kuwait – a Modified Delphi Approach
AlSahow, A., Bulbanat, B., Alhelal, B. A., Alhumoud, K., Alkharaza, A., Al-Otaibi, T., AlRajab, H., Alyousef, A., & Hadi, F. (2024) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s476344 · Cited by 2
Williams, R., Ford, W., James, A., Thomas, K., & Wong, A. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00388-z · Cited by 2
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Stanton, R. C. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.003 · Cited by 2
Tian, L., Fu, S., Li, M., Zhao, X., & Li, H. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1196789 · Cited by 2
Therapeutic Potential of Newer Drugs for Treating Hyperkalemia
Weir, M. R. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04750419 · Cited by 2
Hiperkalemia crónica, diagnóstico y manejo. Consenso colombiano
Rico-Fontalvo, J. E., Rodríguez-González, M. J., Yama, E. Y., Gallego, C., Montejo-Hernández, J. D., Martínez, E. M., Lopera, J. M., Echeverría, L. E., Daza, R., Pieschacón, J. R., et al. (2023) · Archivos de cardiología de México · doi:10.24875/acm.23000160 · Cited by 1
López‐López, A., Regueiro‐Abel, M., Paredes-Galán, E., Johk-Casas, C. A., Viéitez-Flórez, J. M., Elices‐Teja, J., Rivas, J. A., Franco‐Gutiérrez, R., Ríos-Vázquez, R., & González‐Juanatey, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010058 · Cited by 1
Kang, J., Li, S., Su, J., Xiao, Z., Zhang, S., Liu, S., & Ge, P. (2024) · Medicine · doi:10.1097/md.0000000000040917 · Cited by 1
Hida, Y., Imamura, T., & Kinugawa, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082836 · Cited by 1
Sodium Zirconium Cyclosilicate for the Acute Management of Hyperkalemia in the Emergency Department
Gasparovic, N., Buckallew, A. R., & Richter, S. K. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251336245 · Cited by 1
Fang, Y., Wu, Z., Wu, Q., & Chen, G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330340 · Cited by 1
Jia, X., Liu, L., & Wang, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333692 · Cited by 1
Agiro, A., Mu, F., Cook, E. E., Greatsinger, A., Chen, J., Sundar, M., Zhao, A., Colman, E., & Malhotra, A. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00525-7 · Cited by 1
The Endoscopic Removal of a Gastric Bezoar Made of Sodium Zirconium Cyclosilicate Hydrate
Yamauchi, K., Kitae, A., Hara, M., Sugeta, S., Yoneda, K., Ueda, T., Tsuji, K., Morimoto, Y., Shibuya, A., Ohno, T., et al. (2026) · Internal Medicine · doi:10.2169/internalmedicine.6743-25 · Cited by 1
Senni, M., Sciatti, E., Bussalino, E., D’Elia, E., Ravera, M., & Paoletti, E. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001555 · Cited by 1
Imamura, T., Narang, N., & Kinugawa, K. (2023) · International Heart Journal · doi:10.1536/ihj.23-352 · Cited by 1
Dobson, R. (2024) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.3534 · Cited by 1
Blood pressure management in clinically complex scenarios: new horizons for a tailored approach
Pastore, M. C., Liga, R., Diviggiano, E. E., Vitale, C. B., Parlato, A., Amati, F., D’Ascenzi, F., Imbalzano, E., Rinaldi, A., Scicchitano, P., et al. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004025 · Cited by 3
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease
Tamargo, J. L., Caballero, R., & Delpón, E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1891223 · Cited by 1
In pursuit of balance: renin–angiotensin–aldosterone system inhibitors and hyperkalaemia treatment
Sciatti, E., D’Elia, E., Balestrieri, G., D’Isa, S., Iacovoni, A., & Senni, M. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad053 · Cited by 1
An Alternative to Sodium Polystyrene Sulfonate and Patiromer for the Treatment of Hyperkalemia
Sabir, I. N. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.4698 · Cited by 1
Letter to the editor regarding ‘Patiromer for the treatment of hyperkalemia’
Cooper, K. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1828542 · Cited by 1
Zarzuela, D., & Bhalla, N. P. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100651 · Cited by 1
Zarzuela, D., & Chin, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102755 · Cited by 1
Sodium zirconium cyclosilicate in hyperkalaemia: a profile of its use
Paik, J. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00706-0
When ESKD complicates disease management: GI bleeding and other GI illnesses
Salani, M., & Golper, T. A. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12874
A new look at managing hyperkalemia in high-risk patients
Earl, G. L. (2020) · Nursing Critical Care · doi:10.1097/01.ccn.0000660380.54808.53
Analysing Risk in Heart Failure: A Kalium Check
Glenister, R. T., & McCullough, P. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1855
Self-citationAmbruso, S. L. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.03.895
Patel, P. B., & Frankel, A. (2020) · Research Square · doi:10.21203/rs.3.rs-56113/v1
Weinstein, J. J., Girard, L., Lepage, S., McKelvie, R. S., & Tennankore, K. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.210831-f
Goraya, N., & Moran, J. D. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00032022
SZC and SPS, which is Better on Hyperkalemia in Dialysis Patients: A Retrospective StudyPreprint
Yang, J., Guo, Y., Chen, S., Yang, P., Ning, Y., Yao, Y., Xu, G., & Zhang, M. (2023) · Research Square · doi:10.21203/rs.3.rs-2919034/v1
Egyptian Consensus on Hyperkalemia Management: Lessons from Recent Evidences
Abdelhamid, M., Baz, T. E., Hafez, M. H., Hassaballa, M. A., Elsayed, H. M., Sharkawy, M. E., Elkeraie, A. F., Saadi, G. E., & Issak, E. R. (2023) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2023.149036
Penland, R. C., Åstrand, M., Boulton, D. W., & Någård, M. B. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01360-9
Novel Potassium Binders for CKD Patients with Hyperkalemia
Dahlan, R., & Alkatheeri, A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004813
Managing Heart Failure in Chronic Kidney Disease: A Review of Current Literature
Lidgard, B., & Bansal, N. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01048-0
Hyperkalemia in Patients on Peritoneal Dialysis: Clinical Use Experience with New Potassium-Binders
Argentino, G., Iorio, M., Mele, A. A., Camocardi, A., Cascone, E., Liberti, M. E., Sagliocca, A., Pota, A., Russo, L., Sirico, M. L., et al. (2024) · Open Journal of Nephrology · doi:10.4236/ojneph.2024.143030
Blood pressure lowering in kidney disease
Goldman, B., & Tobe, S. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00013-9
Alcázar-Arroyo, R., Crespo‐Leiro, M. G., Bover, J., Oliva, J., Mutiozabal, M. S., Gradari, S., Martinez-Lopez, A., López-Chicheri, B., Vidal-Vilar, N., Aceituno, S., et al. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.10.001
Therapie einer chronischen Hyperkaliämie
Babic, M. (2025) · CardioVasc · doi:10.1007/s15027-024-3713-x
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Khan, S. H., & Weir, M. R. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_3 · Cited by 1
Quah, W. J., Sulong, M. A., Ahmad, G., Koh, H. B., Teoh, C. K., & Ghazi, A. M. (2025) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2024.41
Bilder, G. E., & Brown-O’Hara, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-84831-5_5
Current insights and challenges in the management of hyperkalemia
Ortiz-Cortés, C., & Navarro‐González, J. F. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.10.012
Perspectivas actuales y retos en el tratamiento de la hiperpotasemia
Ortiz-Cortés, C., & Navarro‐González, J. F. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.10.010
Yao, L., Xing, X., Li, Y., Zhang, F., Li, P., Liang, X., & Wang, P. (2022) · Figshare · doi:10.6084/m9.figshare.20372729
Kim, K., Fagerström, J., Chen, G., Lagunova, Z., Furuland, H., & McEwan, P. (2022) · Figshare · doi:10.6084/m9.figshare.20479691
Manejo farmacológico de la ERC: aspectos claves de fármacos poco habituales en Atención Primaria
Delgado, J. I. C., Fernández, M. A., & Martín, F. J. C. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.4.art4
Eitel, I., Emrich, I. E., von Haehling, S., Schleß, B., Schmitt, R., Strutz, F. M., Waßmann, S., & van der Giet, M. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2755-3785
Dong, K., Chen, G., Jian, Y., Su, R., Chen, J., Zhang, C., Huang, K., Tan, X., Peng, B., Huang, P., et al. (2026) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1657585
Lindner, G., Windpessl, M., Pirklbauer, M., Ksiazek, S. H., Kirsch, A. H., Edlinger, R., Säemann, M. D., & Schwarz, C. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02708-w
Shen, N., Zeng, X., Xie, H., Zhang, L. J., Yang, J., Lin, Y., Liu, X., Cai, X., Cao, J., Zhu, Q., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1744687
Self-citationBurton, J. O., Izquierdo, M. J., Linde, C. M., Robles, N. R., Sood, M. M., Allum, A. M., Eudicone, J. M., Dahl, M., & Amin, A. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag158
Yi, Y., Baek, S. H., Lee, J., & Kim, S. (2026) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2026.24.e9
Approach to Hyperkalemia: The Role of Diet and Pharmacological Therapies
Biruete, A., & Fried, L. F. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.03.048 · Cited by 1
Ikeda, N., Nodaira, Y., Kiyosumi, R., Koinuma, K., Iwai, T., Nobe, K., Gen, S., & Kumagai, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145406
Wang, X., Zhang, S., Chen, J.-L., & Zhang, M.-Z. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05324-9
Hyperkalemia in Chronic Kidney Disease: A Nationwide Real-World Evidence Study From Finland
Summanen, M., Asseburg, C., Frederiksen, L. E., Mäkelä, S., Wuorela, M., & Finne, P. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101560
Metadata
- Authors
- Spinowitz, B. S., Fishbane, S., Pergola, P. E., Roger, S. D., Lerma, E. V., Butler, J., von Haehling, S., Adler, S. H., Zhao, J., Singh, B., Lavin, P. T., McCullough, P. A., Kosiborod, M., Packham, D. K., & on behalf of the ZS-005 Study Investigators
- Affiliations
- New York Hospital Queens (US)
- Hofstra University (US)
- Renal Associates PA, San Antonio, Texas;
- Gosford Hospital (AU)
- University of Illinois Chicago (US)
- University of Mississippi (US)
- Universitätsmedizin Göttingen (DE)
- AstraZeneca (United States) (US)
- University of California, Irvine (US)
- Boston Biostatistics Research Foundation, Framingham, Massachusetts;
- Baylor University Medical Center (US)
- The George Institute for Global Health (AU)
- The University of Melbourne (AU)
- Corresponding author
- Spinowitz, Bruce S.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-05-20
- Volume
- 14
- Issue
- 6
- Pages
- 798-809
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC6556727
- OpenAlex
- W2946005791
- Cited by
- 198
- References
- 27
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 33 · 2023: 35 · 2022: 17 · 2021: 28 · 2020: 24 · 2019: 17
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- hyperkalemia, potassium homeostasis, renin-angiotensin-aldosterone system inhibitors, adverse events, hypokalemia, serum potassium, maintenance therapy, drug safety, renal potassium excretion, sodium zirconium cyclosilicate
- MeSH terms
- Adult, Aged, Humans, Hyperkalemia, Male, Potassium, Renin-Angiotensin System, Silicates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
